Antagonising the expression of VEGF in pathological angiogenesis

Bibliography

• CONNOLLY DT, OLANDER JV, HEUVELMAN D et al: Hu- man vascular permeability factor. J. Biol. Chem. (1989) 264:20017–20024.
   PubMed Web of Science ®Google Scholar
• GOSPODAROWICZ D, ABRAHAM JA, SCHILLING J: Isola-tion and characterisation of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stel-late cells. Proc. Natl. Acad. ScL USA (1989) 86:7311–7315.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J et al: Inhibition of vascular endo-thelial growth factor-induced angiogenesis sup-presses tumour growth in vivo. Nature (19 9 3) 362(6423)841–844.
   Google Scholar
• CARMELIET P, FERREIRA V, BREIER G et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1 9 9 6) 380(6573)435–439.
   Google Scholar
• FERRARA N, CARVERMOORE K, CHEN H et al.: Heterozy-gous embryonic lethality induced by targeted inactiva-tion of the VEGF gene. Nature (1996) 380(6573)439–442.
   Google Scholar
• SENGER DR, GALLI SS, DVORAK AM, PERRUZZI CA, HAR-VEY VS, DVORAK HF: Tumour cells secrete a vascular permeability factor that promotes accumulation of as-cites fluid. Science (1983) 219:983–985.
   PubMed Web of Science ®Google Scholar
• DVORAK HF, BROWN LF, DETMAR M, DVORAK AM: Vas-cular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angio-genesis. Am. J. Pathol. (1995) 146 (5) :1029–1039.
   PubMed Web of Science ®Google Scholar
• SENGER DR, CONNOLLY DT, VAN DE WATER L, FEDER J, DVORAK HF: Purification and N-terminal amino acid sequence of guinea pig tumour-secreted vascular per-meability factor. Cancer Res. (1990) 50:1774–1778.
   PubMed Web of Science ®Google Scholar
• NAGY JA, MASSE EM, HERZBERG KT et al.: Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumu-lation. Cancer Res. (1995) 55(2):360–368.
   PubMed Web of Science ®Google Scholar
• ROBERTS WG, PALADE GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell ScL (1995) 108:2369–2379.
   PubMed Web of Science ®Google Scholar
• DOBROGOWSKA DH, LOSSINSKY AS, TARNAWSKI M, VORBRODT AW: Increased blood-brain barrier perme-ability and endothelial abnormalities induced by vas-cular endothelial growth factor. J. Neurocytol. (1998) 27(3):163–173.
   PubMedGoogle Scholar
• CONN G, BAYNE ML, SODERMAN DD et al: Amino acid and cDNA sequences of a vascular endothelial cell mi-togen that is homologous to platelet-derived growth factor. Proc. Natl. Acad. ScL USA (1990) 87(7):2628–2632.
   PubMed Web of Science ®Google Scholar
• DISALVO J, BAYNE ML, CONN G et al.: Purification and characterization of a naturally occurring vascular en-dothelial growth factor placenta growth factor hetero-dimer. J. Biol. Chem. (1995) 270(13):7717–7723.
   PubMedGoogle Scholar
• OLOFSSON B, PAJUSOLA K, KAIPAINEN A et al.: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. ScL USA (1996) 93(6) :2576–2581.
   PubMed Web of Science ®Google Scholar
• KUKK E, LYMBOUSSAKI A, TAIRA S et al.: VEGF-C recep-tor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. De-velopment (1996) 122(12)3829–3837.
   Google Scholar
• JENKINS NA, WOOLLATT E, CRAWFORD J et al: Mapping of the gene for vascular endothelial growth factor-D in mouse and man to the X chromosome. Chromosome Res. (1997) 5(7):502–505.
   PubMedGoogle Scholar
• HOUCK KA, FERRARA N, WINER J, CACHIANES G, LI B, LE-UNG DW: The vascular endothelial growth factor fam-ily: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. (1991) 5(12):1806–1814.
   PubMed Web of Science ®Google Scholar
• HOUCK KA, LEUNG DW, ROWLAND AM, WINER J, FER-RARA N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and prote-olytic mechanisms. J. Biol. Chem. (1992) 267(36):26031–26037.
   PubMed Web of Science ®Google Scholar
• PARK JE, KELLER GA, FERRARA N: Vascular endothelial growth factor (VEGF) isoforms -differential deposition into the subepithelial extracellular matrix and bioac-tivity of extracellular matrix-bound VEGF. Mol. Biol. Cell (1993) 4(12):1317–1326.
   PubMed Web of Science ®Google Scholar
• CHARNOCK-JONES DS, SHARKEY AM, RAJPUT-WILLIAMS J et al.: Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endome-trial carcinoma cell lines. Biol. Reprod. (1993) 48 (5):1120–1128.
   PubMedGoogle Scholar
• POLTORAK Z, COHEN T, SWAN R et al.: VEGF145, a se-creted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. (1997) 272(10:7151–7158.
   PubMedGoogle Scholar
• AKIRI G, NAHARI D, FINKELSTEIN Y, LE SY, ELROYSTEIN 0, LEVI BZ: Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal ini-tiation of translation and alternative initiation of tran-scription. Oncogene (1998) 17(2)227–236.
   Google Scholar
• CLAFFEY KP, SHIH SC, MULLEN A et al.: Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol. Biol. Cell (1998) 9(2)469–481.
   Google Scholar
• LEVY NS, CHUNG SM, FURNEAUX H, LEVY AP: Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. (1998) 273(10:6417–6423.
   PubMedGoogle Scholar
• POTGENS AJG, LUBSEN NH, VANALTENA MC et al.: Cova-lent dimerization of vascular permeability factor vas-cular endothelial growth factor is essential for its biological activity evidence from Cys to Ser mutations. J. Biol. Chem. (1994) 269(52):32879–32885.
   PubMedGoogle Scholar
• PERETZ D, GITAY-GOREN H, SAFRAN M, KIMMEL N, GO-SPODAROWICZ D, NEUFELD G: Glycosylation of vascu-lar endothelial growth factor is not required for its mitogenic activity. Biochem. Biophys. Res. Commun. (1992) 182 (3) :1340–1347.
   PubMedGoogle Scholar
• JAKEMAN LB, WINER J, BENNETT GL, ALTAR CA, FERRARAN: Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest. (1992) 89(1):244–253.
   PubMedGoogle Scholar
• DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT: The fms-like tyrosine kinase, a recep-tor for vascular endothelial growth factor. Science (1992) 255(5047):989–991.
   PubMed Web of Science ®Google Scholar
• TERMAN BI, DOUGHER-VERMAZEN M, CARRION ME et al.: Identification of the KDR tyrosine kinase as a re-ceptor for vascular endothelial cell growth factor. Bio-chem Biophys. Res. Commun. (1992) 187(3):1579–1586.
   PubMed Web of Science ®Google Scholar
• SOKER S, TAKASHIMA S, MIAO HQ, NEUFELD G, KLAGS-BRUN M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascu-lar endothelial growth factor. Cell (1998) 92(6)735–745.
   Google Scholar
• FONG GH, ROSSANT J, GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376(6535)66–70.
   Google Scholar
• KAIPAINEN A, KORHONEN J, PAJUSOLA K et al.: The re-lated FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal en-dothelial cells. J. Exp. Med. (1993) 178(6):2077–2088.
   PubMed Web of Science ®Google Scholar
• CLAUSS M, GERLACH M, GERLACH H et al.: Vascular per-meability factor: a tumor-derived polypeptide that in-duces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J. Exp. Med. (1990) 172:1535–1545.
   PubMed Web of Science ®Google Scholar
• SHEN H, CLAUS M, RYAN J et al.: Characterization of vas-cular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood (1993) 81(l0):2767–2673.
   Google Scholar
• BARLEON B, SOZZANI S, ZHOU D, WEICH HA, MAN-TOVANI A, MARME D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit-i. Blood (1996) 87(8)3336–3343.
   Google Scholar
• BERSE B, BROWN LF, VAN DE WATER L, DVORAK HF, SENGER DR: Vascular permeability factor (vascular en-dothelial growth factor) gene is expressed differen-tially in normal tissues, macrophages, and tumors. Mol Biol. Cell. (1992) 3(2):211–220.
   PubMed Web of Science ®Google Scholar
• SHIFREN JL, DOLDI N, FERRARA N, MESIANO S, JAFFE RB: In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of ac-tion. J. Clin. Endocrinol. Metab. (1994) 79(0:316–322.
   PubMedGoogle Scholar
• MULLER YA, CHRISTINGER HW, KEYT BA, DEVOS AM: The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 angstrom resolution: multiple copy flexibility and receptor binding. Struc-ture (1997) 5(l0):1325–1338.
   Google Scholar
• WIESMANN C, FUH G, CHRISTINGER HW, EIGENBROT C, WELLS JA, DEVOS AM: Crystal structure at 1.7 angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell (1997) 91(5):695–704.
   Google Scholar
• KEYT BA, NGUYEN HV, BERLEAU LT et al.: Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors - generation of receptor-selective VEGF variants by site-directed muta-genesis. J. Biol. Chem. (1996) 271 (l0):5638–5646.
   Google Scholar
• KIM KJ, LI B, HOUCK K, WINER J, FERRARA N: The vascu-lar endothelial growth factor proteins: identification of biologically relevant regions by neutralizing mono-clonal antibodies. Growth Factors (1992) 7(l):53–64.
   Google Scholar
• SIOUSSAT TM, DVORAK HF, BROCK TA, SENGER DR: In-hibition of vascular permeability factor (vascular en-dothelial growth factor) with antipeptide antibodies. Arch. Biochem. Biophys. (1993) 301 (0 :15–20.
   PubMedGoogle Scholar
• TESSLER S, ROCKWELL P, HICKLIN D et al.: Heparin modulates the interaction of VEGF(165) with soluble and cell associated Flk-1 receptors. J. Biol. Chem. (1994) 269(17):12456–12461.
   PubMedGoogle Scholar
• COHEN T, GITAYGOREN H, SHARON R et al.: VEGF(121), a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF re-ceptors of human melanoma cells. J. Biol. Chem. (1995) 270(19):11322–11326.
   PubMed Web of Science ®Google Scholar
• WALTENBERGER J, CLAESSONVVELSH L, SIEGBAHN A, SHIBUYA M, HELDIN CH: Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J. Biol. Chem. (1994) 269(43)26988–26995.
   Google Scholar
• SEYMOUR LW, SHOAIBI MA, MARTIN A et al.: Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells. Lab. Invest. (1996) 75(3):427–437.
   PubMedGoogle Scholar
• XIA P, AIELLO LP, ISHII H et al.: Characterization of vas-cular endothelial growth factor's effect on the activa-tion of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98(9):2018–2026.
   PubMed Web of Science ®Google Scholar
• ENOMOTO T, OKAMOTO T, SATO JD: Vascular endothe-lial growth factor induces the disorganization of actin stress fibers accompanied by protein tyrosine phos-phorylation and morphological change in Balb/c3T3 cells. Biochem. Biophys. Res. Commun. (19 9 4) 202(3):1716–1723.
   Google Scholar
• KROLL J, WALTENBERGER J: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. (1997) 272(50:32521–32527.
   PubMedGoogle Scholar
• SEETHARAM L, GOTOH N, MARU Y, NEUFELD G, YAMA-GUCHI S, SHIBUYA M: A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endo-thelial growth factor VEGF. Oncogene (1995) 10 (1) :135–147.
   PubMedGoogle Scholar
• IGARASHI K, ISOHARA T, KATO T, SHIGETA K, YAMANO T, UNO I: Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. Biochem. Biophys. Res. Commun. (1998) 246(1)95–99.
   Google Scholar
• LANDGREN E, SCHILLER P, CAO Y, CLAESSON-WELSH L: Placenta growth factor stimulates MAP kinase and mi-togenicity but not phospholipase C-gamma and migra-tion of endothelial cells expressing Flt 1. Oncogene (1998) 16(3):359–367.
   PubMed Web of Science ®Google Scholar
• SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endo-thelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (19 9 2) 359 (6398):843–845.
   Google Scholar
• BROGI E, WU TG, NAMIKI A, ISNER JM: Indirect angio-genic cytokines upregulate VEGF and bFGF gene ex-pression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circula-tion (1994) 90(2):649–652.
   PubMedGoogle Scholar
• GOLDBERG MA, SCHNEIDER TJ: Similarities between the oxygen-sensing mechanisms regulating the ex-pression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. (1994) 269(6):4355–4359.
   PubMedGoogle Scholar
• MINCHENKO A, SALCEDA S, BAUER T, CARO J: Hypoxia regulatory elements of the human vascular endothe-lial growth factor gene. Cell. Mol. Biol. Res. (1994) 40(1)35–39.
   Google Scholar
• SEMENZA GL, NEJFELT MK, CHI SM, ANTONARAKIS SE:Hypoxia-inducible nuclear factors bind to an enhan-cer element located 3' to the erythropoietin gene. Proc. Natl. Acad. Sci. USA (1991) 88:5680–5684.
   PubMed Web of Science ®Google Scholar
• ARANY Z, HUANG LE, ECKNER R et al.: An essential rolefor p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA (1996) 93(23):12969–12973.
   PubMed Web of Science ®Google Scholar
• FORSYTHE JA, JIANG BH, IYER NV et al.: Activation ofvascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. (1996) 16(9)4604–4613.
   Google Scholar
• EMA M, TAYA S, YOKOTANI N, SOGAWA K, MATSUDA Y, FUJIIKURIYAMA Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 al-pha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Nall Acad. Sci. USA (1997) 94(9):4273–4278.
   PubMed Web of Science ®Google Scholar
• DAMERT A, IKEDA E, RISAU W: Activator-protein-1 bind-ing potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J. (1997) 327 (Part 2):419–423.
   Google Scholar
• ILIOPOULOS 0, LEVY AP, JIANG C, KAELIN WG, Jr., GOLDBERG MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA (1996) 93 (20): 10595–10599 .
   Google Scholar
• MANISCALCO WM, WATKINS RH, D'ANGIO CT, RYAN RM:Hyperoxic injury decreases alveolar epithelial cell ex-pression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung. Am. J. Respir. Cell. Mol. (1997) 16(5):557–567.
   Google Scholar
• TAKAGI H, KING GL, ROBINSON GS, FERRARA N, AIELLO LP: Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and en-dothelial cells. Invest. Ophthalmol Visual Sci. (1996) 37(11)2165–2176.
   Google Scholar
• LEVY NS, GOLDBERG MA, LEVY AP: Sequencing of the human vascular endothelial growth factor (VEGF) 3' untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim. Biophys. Acta - Gene Structure Expression (1997) 1352(2):167–173.
   PubMedGoogle Scholar
• MUKHOPADHYAY D, TSIOKAS L, ZHOU XM, FOSTER D, BRUGGE JS, SUKHATME VP Hypoxic induction of hu-man vascular endothelial growth factor expression through c-Src activation. Nature (1995) 375 (6532) 577–581
   PubMed Web of Science ®Google Scholar
• GLEADLE JM, RATCLIFFE PJ: Induction of hypoxia- inducible factor-1, erythropoietin, vascular endothe-lial growth factor, and glucose transporter-1 by hy-poxia: evidence against a regulatory role for Src kinase. Blood (1997) 89(2):503–509.
   PubMed Web of Science ®Google Scholar
• MAZURE NM, CHEN EY, LADEROUTE KR, GIACCIA AJ In- duction of vascular endothelial growth factor by hy-poxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood (1997) 90(9)3322–3331.
   Google Scholar
• JIANG BH, AGANI F, PASSANITI A, SEMENZA GL: V-SRCinduces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. (1997) 5 7 (23)5328–5335.
   Google Scholar
• HASHIMOTO E, OGITA T, NAKAOKA T, MATSUOKA R,TAKAO A, KIRA Y: Rapid induction of vascular endothe-lial growth factor expression by transient ischemia in rat heart. Am. J. Physiol. (Heart Circ. Physiol) (1994) 36(5):H1948–1954.
   Google Scholar
• BANAI S, SHWEIKI D, PINSON A, CHANDRA M, LAZARO-VICI G, KESHET E: Upregulation of vascular endothelial growth factor expression induced by myocardial is-chaemia: Implications for coronary angiogenesis. Car-diovasc. Res. (1994) 28 (8) :1176–1179.
   PubMed Web of Science ®Google Scholar
• PEER J, SHWEIKI D, ITIN A, HEMO I, GNESSIN H, KESHETE: Hypoxia-induced expression of vascular endothe-lial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. (1995) 72 (6):638–645.
   PubMed Web of Science ®Google Scholar
• LI J, PERRELLA MA, TSAI JC et al.: Induction of vascularendothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J. Biol. Chem. (1995) 270(1):308–312.
   PubMedGoogle Scholar
• STAVRI GT, ZACHARY IC, BASKERVILLE PA, MARTIN JF,ERUSALIMSKY JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells : syner-gistic interaction with hypoxia. Circulation (1995) 92 (1):11–14.
   PubMed Web of Science ®Google Scholar
• PERTOVAARA L, KAIPAINEN A, MUSTONEN T et al.: Vas-cular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. (1994) 269(9):6271–6274.
   PubMed Web of Science ®Google Scholar
• PEPPER MS, VASSALLI JD, ORCI L, MONTESANO R: Bipha-sic effect of transforming growth factor-beta 1 on in vi-tro angiogenesis. Exp. Cell Res. (1993) 204(2)356–363.
   Google Scholar
• IIJIMA K, YOSHIKAWA N, CONNOLLY DT, NAKAMURA H: Human mesangial cells and peripheral blood mono-nuclear cells produce vascular permeability factor. Kidney Intern. (1993) 44(5):959–966.
   PubMedGoogle Scholar
• WILLIAMS B, BAKER AQ, GALLACHER B, LODWICK D: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension (1995) 25 (5) :913–917.
   PubMed Web of Science ®Google Scholar
• NAFTILAN AJ, PRATT RE, DZAU VJ: Induction of platelet derived growth factor A chain and c-myc gene expres-sions by angiotensin II in cultured rat smooth muscle cells. J. Clin. Invest. (1989) 83:1419–1424.
   PubMed Web of Science ®Google Scholar
• GOLDMAN CK, KIM J, WONG WL, KING V, BROCK T,GILLESPIE GY: Epidermal growth factor stimulates vas-cular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multi-forme pathophysiology. Mol Biol. Cell (1993) 4 (1) :121–133.
   PubMed Web of Science ®Google Scholar
• DETMAR M, BROWN LF, CLAFFEY KP et al. Overexpres- sion of vascular permeability factor/vascular endothe-lial growth factor and its receptors in psoriasis. J. Exp. Med. (1994) 180(3):1141–1146.
   PubMed Web of Science ®Google Scholar
• HARADA S, NAGY JA, SULLIVAN KA et al.: Induction of vascular endothelial growth factor expression by prostaglandin E2 and El in osteoblasts. J. Clin. Invest. (1994) 93(6):2490–2496.
   PubMedGoogle Scholar
• PEPPER MS, FERRARA N, ORCI L, MONTESANO R: Leuke-mia inhibitory factor (LIF) inhibits angiogenesis in vi-tro. J. Cell Sci. (1995) 108 (Part 1):73–83.
   Google Scholar
• HU DE, FAN TPD: Suppression of VEGF-induced angio-genesis by the protein tyrosine kinase inhibitor, lav-endustin A. Br. J. Pharmacol. (1995) 114(2):262–268.
   PubMedGoogle Scholar
• TUDER RM, FLOOK BE, VOELKEL NF: Increased gene ex-pression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia - modulation of gene expression by nitric oxide. J. Clin. Invest. (1995) 95(4):1798–1807.
   PubMed Web of Science ®Google Scholar
• WEBB NJA, BOTTOMLEY MJ, WATSON CJ, BRENCHLEY PEC: Vascular endothelial growth factor (VEGF) is re-leased from platelets during blood clotting: implica-tions for measurement of circulating VEGF levels in clinical disease. Chn. Sci. (1998) 94:395–404.
   Google Scholar
• PLUDA JM, PARKINSON DR: Clinical implications of tumor-associated neovascularization and current anti-angiogenic strategies for the treatment of malignan-cies of pancreas. Cancer (1996) 78(3):680–687.
   PubMedGoogle Scholar
• TOI M, KONDO S, SUZUKI H et al.: Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer (1996) 77 (6):1101–1106.
   PubMedGoogle Scholar
• OBRIEN T, CRANSTON D, FUGGLE S, BICKNELL R, HARRISAL: Different angiogenic pathways characterize super-ficial and invasive bladder cancer. Cancer Res. (1995) 55 (3):510–513.
   PubMedGoogle Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, EL-LIS LM: Expression of vascular endothelial growth fac-tor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55 (18) 3964–3968
   PubMed Web of Science ®Google Scholar
• ANAN K, MORISAKI T, KATANO M et al.: Vascular endo-thelial growth factor and platelet-derived growth fac-tor are potential angiogenic and metastatic factors in human breast cancer. Surgery (1996) 119(3):333–339.
   PubMedGoogle Scholar
• DVORAK HF, SIOUSSAT TM, BROWN LF et al: Distribu-tion of vascular permeability factor (vascular endothe-lial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. (1991) 174(5):1275–1278.
   PubMedGoogle Scholar
• HLATKY L, TSIONOU C, HAHNFELDT P, COLEMAN CN: Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothe-lial growth factor up-regulation and protein expres-sion. Cancer Res. (1994) 54(23):6083–6086.
   PubMedGoogle Scholar
• MAXWELL PH, DACHS GU, GLEADLE JM et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Nati Acad. Sci. USA (1997) 94(15):8104–8109.
   PubMedGoogle Scholar
• RAK J, MITSUHASHI Y, BAYKO L et al. Mutant ras onco- genes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. (1995) 55 (20) 4575–4580
   PubMed Web of Science ®Google Scholar
• AGANI F, KIRSCH DG, FRIEDMAN SL, KASTAN MB, SE-MENZA GL: p53 does not repress hypoxia-induced transcription of the vascular endothelial growth fac-tor gene. Cancer Res. (1997) 57(20)4474–4477.
   Google Scholar
• GASPARINI G, TOI M, GION M et al.: Prognostic signifi-cance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. (1997) 89 (2) :139–147.
   PubMedGoogle Scholar
• OBERMAIR A, KUCERA E, MAYERHOFER K et al: Vascularendothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int. J. Cancer (1997) 74(4):455–458.
   PubMed Web of Science ®Google Scholar
• TOI M, HOSHINA S, TAKAYANAGI T, TOMINAGA T: Asso-ciation of vascular endothelial growth factor expres-sion with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. (1994) 85 (101045–1049.
   Google Scholar
• MAEDA K, CHUNG YS, OGAWA Y et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (1996) 77(5)858–863.
   Google Scholar
• OBERMAIR A, KOHLBERGER P, BANCHER-TODESCA D et al.: Influence of microvessel density and vascular per-meability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol On-col. (1996) 63(2):204–209.
   PubMed Web of Science ®Google Scholar
• INOUE K, OZEKI Y, SUGANUMA T, SUGIURA Y, TANAKA S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma: asso-ciation with angiogenesis and tumor progression. Cancer (1997) 79(2):206–213.
   PubMed Web of Science ®Google Scholar
• CLAFFEY KP, BROWN LF, DELAGUILA LF et al.: Expres-sion of vascular permeability factor/vascular endothe-lial growth factor by melanoma cells increases tumor
   Google Scholar
• BOTTOMLEY MJ, HOLT PLJ, WATSON CJ, WEBB NJA, BRENCHLEY PEC: Vascular endothelial growth factor mediates synovial inflammation. Arthr. Rheum. (1996) 39(N9). Suppl. S131.
   Google Scholar
• FAVA RA, OLSEN NJ, SPENCER-GREEN G et al.: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. (1994) 180(0:341–346.
   PubMedGoogle Scholar
• KOCH AE, HARLOW LA, HAINES GK et al. Vascular endo- thelial growth factor - a cytokine modulating endothe-lial function in rheumatoid arthritis. J. Immunol. (1994) 152(8)4149–4156.
   Google Scholar
• NAGASHIMA M, YOSHINO S, ISHIWATA T, ASANO G: Role of vascular endothelial growth factor in angio-genesis of rheumatoid arthritis. J. Rheumatol (1995) 22(9):1624–1630.
   PubMed Web of Science ®Google Scholar
• BOTTOMLEY MJ: Vascular endothelial growth factor, placental growth factor and their heterodimers are present in synovial fluid: implications for the patho-genesis of synovial inflammation in patients with ar-thropathy [PhD Thesis, University of Manchester]. (1998).
   Google Scholar
• PARK JE, CHEN HH, WINER J, HOUCK KA, FERRARA N: Placenta growth factor - potentiation of vascular endo-thelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. (1994) 269(40:25646–25654.
   PubMedGoogle Scholar
• WEBB NJA, MYERS CR, WATSON CJ, BOTTOMLEY MJ, BRENCHLEY PEC: Activated human neutrophils ex-press vascular endothelial growth factor (VEGF). Cyto-kine (1998) 10:254–257.
   PubMedGoogle Scholar
• JACKSON JR, MINTON JA, HO ML, WET N, WINKLER JD: Ex-pression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and inter-leukin lbeta. j Rheumatol. (1997) 24 (7) :1253–1259.
   PubMedGoogle Scholar
• AIELLO LP, AVERY RL, ARRIGG PG et al.: Vascular endo-thelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl. J. Med. (1994) 331(22):1480–1487.
   PubMed Web of Science ®Google Scholar
• KHALIQ A, FOREMAN D, AHMED A et al.: Increased ex-pression of placenta growth factor in proliferative dia-betic retinopathy. Lab. Invest. (1998) 78 (1): 109–116 .
   PubMed Web of Science ®Google Scholar
• PIERCE EA, AVERY RL, FOLEY ED, AIELLO LP, SMITH LEH: Vascular endothelial growth factor/vascular perme-ability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA (1995) 92 (3) 905–909.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al: Suppression of retinal neovascularization in vivo by inhibition of vas-cular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA (1995) 92(23):10457–10461.
   PubMed Web of Science ®Google Scholar
• SONE H, KAWAKAMI Y, OKUDA Y eta].:Vascular endo- thelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glu-cose deprivation in cultured bovine retinal pigmented epithelial cells. Biochem. Biophys. Re. Commun. (1996) 221(0:193–198.
   Google Scholar
• NATARAJAN R, BAT W, LANTING L, GONZALES N, NADLER J: Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am. J. Physiol. (1997) 273(5 Pt 2):H2224–2231.
   Google Scholar
• HIRATA C, NAKANO K, NAKAMURA N et al.: Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Bio-chem. Biophys. Res. Commun. (1997) 236(3):712–715.
   PubMed Web of Science ®Google Scholar
• LU M, KUROKI M, AMANO S et al.: Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. (1998) 101(6):1219–1224.
   PubMed Web of Science ®Google Scholar
• PRESTA LG, CHEN H, OCONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor mono-clonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• 4-anilinoquinazoline derivatives. Exp. Opin. Thar. Pat-ents (1998) 8(4):475–478.
   Google Scholar